Solventum (SOLV) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $1.45
- Estimate
- $1.34
- Surprise
- +7.9%
- Revenue (period 2026-09-30)
- $1.95B
- Score today
- 5.1/10
Revenue source: xbrl.
How the report landed
Solventum (SOLV) beat the $1.34 estimate with adjusted EPS of $1.45 — a clear 7.9% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates SOLV Sell at 5.1/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +7.9% surprise compares with a +14.0% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Product: MedSurg segment (57.9%)
- Analyst target reached - limited upside remaining
- Near 52-week high (3.0% away)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $91.36
- Stop
- $85.10
The stock trades at 98.0× trailing but 12.0× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
SOLV at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $14.84B
- P/E (fwd)
- 12.0
- P/E (ttm)
- 98.0
- 52-week range
- $62.38–$94.16
- Off 52-week high
- 3.0%
- RSI (14)
- 62
- Volume vs avg
- 0.93×
- Score today
- 5.1/10